Clinical trials: Invasive Fungal Disease
Candidemia, Invasive Candidiasis
This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis
The primary objective is to estimate global response rate. Clinical, microbiological and global response rates and its 95% confidence intervals will be computed. No hypotheses will be tested.
- Trial name
- NCT00548262
- Testing
- Anidulafungin, Voriconazole
- Where
- 13 sites in Brazil, Chile and 3 more
- Volunteers
- 54 people
- Sponsor
- Pfizer
Invasive Candidiasis
Comparison of Uncomplicated Candidemia Therapy Duration in Children and Adults
The goal of this clinical trial is to compare antifungal therapy duration in uncomplicated candidemia. The specific aims are: Compare the desirability of outcome ranking in patients with uncomplicated candidemia randomized to 7…
- Trial name
- COUNT (NCT05763251)
- Testing
- therapy duration
- Where
- 22 sites in United States, Australia
- Volunteers
- 420 people
- Sponsor
- Arkansas Children's Hospital Research Institute
Candidemia
Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins
The purpose of this pharmacokinetic (PK) and pharmacodynamic (PD) study is: To study the rate and duration of serum cidal activity of caspofungin (CFG) and micafungin (MFG) against Candida isolates from the subject and against…
- Trial name
- NCT00839540
- Testing
- micafungin, Caspofungin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Gary E. Stein, Pharm.D.
Invasive Fungal Infections
A Bioequivalence Study of APX001 High-load and Low-load Tablets
A study to learn about the bioequivalence (the biochemical similarity of two medicines that share the same active ingredient and desired outcome for patients) of the study medicine called APX001 in healthy participants.
- Trial name
- NCT05491733
- Testing
- APX001, APX001A
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Basilea Pharmaceutica
Bacteremia, Sepsis
Impact of Rapid Pathogen Identification From Blood Cultures (RABbIT)
Septic shock carries high mortality, which may be exacerbated by inappropriate initial therapy. Inappropriate therapy may result from unanticipated antimicrobial resistance.
- Conditions
- Bacteremia, Sepsis, Fungemia, Blood Stream Infection
- Trial name
- RABbIT (NCT02743585)
- Testing
- Filmarray Blood Culture ID (BCID) panel, Rosco Diagnostica ESBL/carbapenemase screen kit
- Where
- Singapore
- Volunteers
- 832 people
- Sponsor
- Tan Tock Seng Hospital
Invasive Fungal Disease, Graft Versus Host Disease
Posaconazole Tablet As Primary Prophylaxis of HSCT Patients with Gastrointestinal GVHD
This is a prospective investigation using a nonrandomized, single-arm design. Posaconazole tablet will be given at a dose of 300mg q12h on day 1 and 300mg qd from day 2 for patients who receive HSCT as the primary prophylaxis of…
- Conditions
- Invasive Fungal Disease, Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation
- Trial name
- NCT06698211
- Testing
- Posaconazole tablet
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Invasive Aspergillosis
Correlation Between Circulating Galactomannan and Beta-D-glucan and Clinical Outcome of Invasive Aspergillosis
The investigators hypothesize that early galactomannan and beta-D-glucan features, namely the height of the initial value at the time of diagnosis and the subsequent rate of marker decay within the first week(s) following therapy…
- Trial name
- NCT01176071
- Volunteers
- 50 people
- Sponsor
- University Hospital, Gasthuisberg
IFI
Treatment Method Research of Invasive Pulmonary Fungal Infection
The purpose of this study is to Comparison clinical efficiency with IPFI patients who treated by different protocols(empirical therapy or preemptive therapy) in ICU.
- Trial name
- 4056 (NCT01693887)
- Where
- 4 sites in China
- Volunteers
- 7 people
- Sponsor
- West China Hospital
Streptococcal Sepsis, Invasive Group A Beta-Haemolytic Streptococcal Disease
Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections
This study aims to emulate a hypothetical target pragmatic multi-center, non-blinded trial of adult inpatients in the PINC AITM dataset with B-lactam treated culture confirmed monomicrobial invasive Group A streptococcus (GAS)…
- Conditions
- Streptococcal Sepsis, Invasive Group A Beta-Haemolytic Streptococcal Disease, Necrotizing Soft Tissue Infection, Infection, Bloodstream
- Trial name
- iGASAntitox (NCT06126263)
- Testing
- Linezolid, Clindamycin
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Invasive Aspergillosis
Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on Invasive Aspergillosis
The objective of this study is to evaluate the efficacy and safety of intravenous micafungin for the treatment of proven or probable fungal infections caused by Aspergillus sp.
- Trial name
- NCT02646774
- Testing
- Micafungin
- Where
- 19 sites in China
- Volunteers
- 43 people
- Sponsor
- Astellas Pharma China, Inc.
Candidiasis, Esophageal, Candidiasis, Invasive
A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074)
The study estimates the safety, efficacy, and pharmacokinetics of caspofungin (MK-0991) in Japanese children and adolescents with documented Candida or Aspergillus infections.
- Conditions
- Candidiasis, Esophageal, Candidiasis, Invasive, Aspergillosis
- Trial name
- NCT01165320
- Testing
- Caspofungin
- Volunteers
- 20 people
- Sponsor
- Merck Sharp & Dohme LLC
Aspergillosis and Haematological Malignancy
PET/CT Guided Antifungal Stewardship in Invasive Pulmonary Aspergillosis
OPTIFIL is a pilot prospective multicenter study based over the hypothesis that the normalization of the functional imaging 18F-FDG-PET/CT during the Invasive pulmonary aspergillosis (IPA) could occur earlier than that of…
- Trial name
- OPTIFIL (NCT02955966)
- Testing
- imaging 18F-FDG-PET/CT, Blood collection
- Where
- France
- Volunteers
- 51 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Graft vs Host Disease
Evaluation of Antifungal Prophylaxis on Graft-versus-host Disease (GVHD) Patients
Antifungal prophylaxis should be used in patients being treated with glucocorticoids for graft-versus-host disease (GVHD) following allogeneic hematopoietic stem-cell transplantation (HSCT).
- Trial name
- ITRAG (NCT01282879)
- Testing
- Itraconazole
- Where
- 9 sites in South Korea
- Volunteers
- 36 people
- Sponsor
- Samsung Medical Center
Meningitis, Meningococcal Meningitis
Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older
Primary objectives: To describe the antibody responses to meningococcal serogroups A, C, Y, and W 135, measured by serum bactericidal assay using human complement (hSBA) and baby rabbit complement (rSBA), induced by a single dose…
- Conditions
- Meningitis, Meningococcal Meningitis, Meningococcal Infections, Invasive Meningococcal Disease
- Trial name
- NCT01732627
- Testing
- Meningococcal Polysaccharide (A, C, Y, and W 135) Tetanus Protein Conjugate Vaccine, Meningococcal Polysaccharide Vaccine, Groups A, C, Y, W 135 Combined
- Where
- 12 sites in United States
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Salmonella Infections
A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants
The purpose of this study is to evaluate the safety, reactogenicity, and immune response induced by the GlaxoSmithKline Biologicals SA (GSK) Vaccines Institute for Global Health (GVGH) invasive nontyphoidal Salmonella-typhoid…
- Trial name
- NCT07286370
- Testing
- Low dose of iNTS-TCV, Full dose of iNTS-TCV, TYPHIBEV
- Where
- The Gambia
- Volunteers
- 537 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Fusariosis
Markers of Infection and Resistance in Invasive Fusariosis
In recent decades, invasive fusarioses have been emerging fungal pathologies with high mortality. The prognosis depends on the speed of the diagnosis, but currently biological diagnosis is mainly based on fungal culture, no…
- Trial name
- FUSIMIR (NCT04937751)
- Testing
- biomarkers
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Central Hospital, Nancy, France
Candidemia
An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia
This is a multicenter, open-label, non-comparative, single-arm study to evaluate the efficacy and safety of APX001 for the first-line treatment for candidemia including suspected or confirmed antifungal-resistant candidemia in…
- Trial name
- NCT03604705
- Testing
- APX001
- Where
- 29 sites in United States, Belgium and 3 more
- Volunteers
- 21 people
- Sponsor
- Basilea Pharmaceutica
Fungal Infections, Invasive Pulmonary Aspergillosis
A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)
The purpose of this study is to evaluate the safety and efficacy of posaconazole (POS) versus voriconazole (VOR) in the treatment of adults and adolescents with invasive aspergillosis (IA).
- Trial name
- NCT01782131
- Testing
- Posaconazole, Voriconazole
- Volunteers
- 585 people
- Sponsor
- Merck Sharp & Dohme LLC
Invasive Candidiasis, Candidemia
Genetic Susceptibility Factors for Candidemia.
This is a prospective case-control physiopathological study, which main objective is to determine the genetic host factors predisposing to candidemia.
- Conditions
- Invasive Candidiasis, Candidemia, Genetic Predisposition to Disease
- Trial name
- NCT02841501
- Testing
- Analysis of genetic polymorphisms
- Where
- France
- Volunteers
- 453 people
- Sponsor
- University Hospital, Lille
Meningococcal Disease, Invasive
Adolescent MenACWY Booster Study
This study is to confirm non-inferiority of the three MenACWY vaccines (Menveo, Menactra or Nimenrix) in adolescents, and to identify whether the number of previous doses of MenC influences the response to the MenACWY vaccine.
- Trial name
- NCT03694405
- Testing
- MenACWY-CRM, MenACWY-DT, MenACWY-TT
- Where
- 3 sites in Canada
- Volunteers
- 244 people, healthy volunteers welcome
- Sponsor
- Canadian Immunization Research Network